Chronic Spontaneous Urticaria in the Era of Targeted Therapy: From Pathogenic Mechanisms to Precision Medicine.

Rhapsido (remibrutinib) - Novartis

Xolair (omalizumab) - Roche, Novartis

barzolvolimab (CDX-0159) - Celldex

briquilimab (JSP191) - Jasper Therapeutics

Dupixent (dupilumab) - Sanofi, Regeneron

http://www.ncbi.nlm.nih.gov/pubmed/42797344

Joanna Gorka-Dynysiewicz; Klara Andrzejczak; Wiktor Witkowski

Sep 27, 2026